89026-79-9

Basic information

• Product Name: (6-Bromo-pyridin-2-yl)-methyl-amine
• Synonyms: (6-Bromo-pyridin-2-yl)-methyl-amine;6-bromo-N-methyl-2-Pyridinamine
• CAS NO: 89026-79-9
• Molecular Formula: C₆H₇BrN₂
• Molecular Weight: 187.04
• Mol File: 89026-79-9.mol
• Article Data: 14

Chemical Properties

• Melting Point: 62-63 °C
• Boiling Point: 271.9 °C at 760 mmHg
• Flash Point: 118.3 °C
• Appearance: /
• Density: 1.581 g/cm³
• Storage Temp.: 2-8°C
• PKA: 3.20±0.10(Predicted)
• CAS DataBase Reference: (6-Bromo-pyridin-2-yl)-methyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (6-Bromo-pyridin-2-yl)-methyl-amine(89026-79-9)
• EPA Substance Registry System: (6-Bromo-pyridin-2-yl)-methyl-amine(89026-79-9)

Safety Data

• Hazardous Substances Data: 89026-79-9(Hazardous Substances Data)

Usage

General Description

(6-Bromo-pyridin-2-yl)-methyl-amine, also known as 2-(6-Bromo-pyridin-2-ylamino)-ethylamine, is a chemical compound with the molecular formula C7H9BrN2. It is a derivative of pyridine with a bromo substituent at the 6th position and an aminoethyl group attached to the 2nd carbon. (6-Bromo-pyridin-2-yl)-methyl-amine is commonly used as a building block in organic synthesis and pharmaceutical research. It is known for its potential application in the development of various biologically active molecules and drug candidates. Additionally, it can be utilized in the synthesis of diverse heterocyclic compounds and as a reagent in chemical reactions.

Upstream product

• 19798-81-3 2-Amino-6-bromopyridine 
• 74-88-4 methyl iodide 
• 626-05-1 2,6-Dibromopyridine 
• 593-51-1 methylamine hydrochloride 
• 13061-96-6 dihydroxy-methyl-borane 
• 74-89-5 methylamine 
• 817618-19-2 tert-butyl (6-bromopyridin-2-yl)(methyl)carbamate 

Downstream Products

• 4597-87-9 2-(N-methylamino)pyridine 
• 1589588-44-2 C₅₄H₅₁N₁₅O₃ 
• 1589588-42-0 C₅₄H₄₂N₁₈ 
• 1589588-40-8 C₅₄H₅₁N₁₅ 
• 1589588-32-8 C₅₁H₄₅N₁₅ 
• 1589588-07-7 C₁₈H₁₅BrN₆ 
• 1589588-05-5 C₁₈H₁₈BrN₅ 
• 1589588-15-7 C₁₈H₁₈BrN₅O 
• 1589588-13-5 C₁₇H₁₆BrN₅ 
• 1227094-87-2 1-(3,4-dichlorobenzyl)-3-(2-(6-(methylamino)pyridin-2-yl)ethyl)urea 
• 1220596-13-3 benzyl 2-(6-(methylamino)pyridin-2-yl)ethylcarbamate 
• 935397-21-0 ethyl (Z)-2-ethoxy-3-[4-(6-methylaminopyrid-2-yl)phenyl]acrylate 
• 801239-54-3 2-(4-{3-[2-(2-tert-butoxycarbonylamino-ethoxy)-ethoxy]-propyl}-benzenesulfonylamino)-3-{4-[2-(6-methylamino-pyridin-2-yl)-ethyl]-benzoylamino}-propionic acid tert-butyl ester 
• 801239-52-1 2-(benzenesulfonyl-{2-[2-(3-tert-butoxycarbonylamino-propoxy)-ethoxy]-ethyl}-amino)-3-{4-[2-(6-methylamino-pyridin-2-yl)-ethyl]-benzoylamino}-propionic acid tert-butyl ester 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES

A compound of Formula I useful as an emitter in OLED is disclosed.

Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: Structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1)

The recent discovery of allosteric modulators of the CB1 receptor including PSNCBAM-1 (4) has generated significant interest in CB1 receptor allosteric modulation. Here in the first SAR study on 4, we have designed and synthesized a series of analogs focusing on modifications at two positions. Pharmacological evaluation in calcium mobilization and binding assays revealed the importance of alkyl substitution at the 2-aminopyridine moiety and electron deficient aromatic groups at the 4-chlorophenyl position for activity at the CB1 receptor, resulting in several analogs with comparable potency to 4. These compounds increased the specific binding of [3H]CP55,940, in agreement with previous reports. Importantly, 4 and two analogs dose-dependently reduced the Emaxof the agonist curve in the CB1 calcium mobilization assays, confirming their negative allosteric modulator characteristics. Given the side effects associated with CB1 receptor orthosteric antagonists, negative allosteric modulators provide an alternative approach to modulate the pharmacologically important CB1 receptor.